Feedback
BD Club Max
×
Gastrointestinal infection (GI) - September 16, 2022

FecalSwab™ is now validated on BD Enteric Portfolio for BD MAX™ System

Add to fav remove to fav Add to favorites Thumb up remove thumb up Like the content

FecalSwab™ Collection, Transport and Preservation System is now validated on BD enteric portfolio for BD MAX™ System

Our enteric portfolio is ever evolving to meet your needs!

BD has recently validated the FecalSwab™ specimen as a sample alternative to help enable flexible gastroenteritis testing and continuously adapt to customers’ requirements. This new type of sample is approved on the full BD MAX™ enteric suite: BD MAX™ Enteric Bacterial and Extended Bacterial Panels, BD MAX™ Enteric Viral Panel, BD MAX™ Enteric Viral Panel-NR and BD MAX™ Enteric Parasite Panel.

With the targeted syndromic approach of the BD enteric portfolio for the BD MAX™ System, you can now benefit from the flexibility of its menu covering pathogens responsible for more than 90% of infectious diarrhea1, as well as the option to test from both FecalSwab™ and stool samples alike.
This new claim available on BD enteric portfolio is a key milestone to further support the ease of sample preparation introducing the possibility for specimen pipetting and reinforces the ease of use on the BD MAX™ System.

This consolidation of sample types across molecular and culture testing is also one step forward towards the BD vision of the integration of molecular testing within the automated microbiology workflow supported by BD Kiestra™.

FecalSwab™ incorporates a modified Cary-Blair medium specifically designed for the recovery, preservation and detection of enteric pathogens that is mainly sold and distributed by BD and Copan.

1.Sidoti F, Rittà M, Costa C, et al. Diagnosis of viral gastroenteritis : limits and potential of currently available procedures. J Infect Dev Ctries 2015;9:551-561.

By reading this content you are acknowledging our forward looking statement.

Why join BD MAX™ Club?

Connect with professionals from around the world BD MAX™ Club members represent a community of professionals in infectious diseases and molecular diagnostics. With regional meet-ups and live webinars from global experts, expand your laboratory’s network and collaborate with worldwide colleagues.

Tailored medical and technical expertise Whether you need compelling scientific research or tutorials for troubleshooting on the BD MAX™ System, BD MAX™ Club is here to accompany your molecular diagnostics journey. Log in to your BD MAX™ Club account anywhere, anytime to access our information database.

Exclusive members’ perks BD MAX™ Club membership unlocks doors to exclusive webinars and collaboration with industry leading experts. Engage with your colleagues in the molecular community and exchange with the BD research and development team.

Join BD MAX™ Club

Latest news

How can BD MAX™ Club support your lab’s challenges?

All topics

Forward Looking Statement

The information included on this website and other information provided from time to time through webcasts, conference calls, securities analyst meetings, road show presentations, investor conferences, newsletters and similar events and communications contains forward-looking statements (as defined under Federal securities laws) based on current expectations and assumptions that involve risks and uncertainties. If the risks or uncertainties ever materialize or the assumptions prove incorrect, the results of BD may differ materially from those expressed or implied by such forward-looking statements and assumptions. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, future product development, regulatory approvals, competitive position and expenditures.

All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Many of these risks and uncertainties are beyond the company’s control. For a discussion of certain factors that could cause our actual results to differ from our expectations in any forward-looking statements see our latest Annual Report on Form 10-K and other filings with the SEC. BD expressly disclaims any undertaking to update or revise any forward looking statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.